Regor Therapeutics, a clinical stage biotechnology company dedicated to the 
discovery of innovative medicines to treat cancer, immune disorders and 
metabolic diseases, announces the successful completion of $90 million Series B 
financing.

Founded in July of 2018 by a group of veteran drug hunters with extensive 
research and executive leadership experiences at top multinational 
pharmaceutical companies, Regor aims to establish world-class innovation 
capabilities and is committed to delivering clinically differentiated, best- 
and first-in-class drugs to serve patients globally.  By leveraging CARD, 
Computer Accelerated Rational Discovery, a proprietary enabling technology 
platform, the team has successfully advanced numerous discovery programs in a 
dramatically accelerated fashion, including from ideas to a clinical start in 
two years. 

The Series B financing was led by Lilly Asia Ventures and included 
participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex 
Ventures China. Regor Therapeutics was established with initial series A 
strategic investment from Qilu Pharmaceutical Group, a well-known Chinese 
pharmaceutical company.

"We are very pleased with the strong support from leading life science 
investment firms in this financing round. We are now in a strong position to 
advance pre-clinical and clinical studies of multiple programs," said Dr. 
Xiayang Qiu, Founder and CEO of Regor. "We are looking forward to long-term 
collaborations with our investors, as we aim to improve the treatment outcomes 
for worldwide patients of chronic diseases, cancer and other life-threatening 
diseases." 

"We are proud to support Regor Therapeutics' world-class team to expand its 
efforts across a larger number of programs and therapeutic areas to develop 
tomorrow's life-saving treatments," said Dr. Yi Shi, managing partner of Lilly 
Asia Ventures. 

"With the next decade comes a historical moment for China's leap upwards. We 
are delighted to collaborate with veteran scientists, leading entrepreneurs and 
investment partners in biopharma industry. Together we are working hard for a 
better world by innovative and transformative medicines which make meaningful 
impacts to patients globally," said Mr. Andy Lin, founding partner of Loyal 
Valley Capital.

About Regor Therapeutics Group

Regor Therapeutics is a clinical stage company dedicated to the discovery and 
development of innovative and clinically differentiated medicines by leveraging 
the proprietary CARD (Computer Accelerated Rational Discovery) Platform, 
seamlessly integrating structural biology, computational chemistry, therapeutic 
biology, medicinal chemistry, and clinical development. Regor has assembled a 
world-class scientific team and demonstrated high efficiency in producing best- 
and first-in-class molecules. 

About Lilly Asia Ventures

Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm founded 
in 2008, with offices in Shanghai, Hong Kong, and Palo Alto. Our vision is to 
become the trusted partner for exceptional entrepreneurs seeking smart capital 
and to build great companies developing breakthrough products that treat 
diseases and improve human health.

About Loyal Valley Capital

Loyal Valley Capital ("LVC"), founded in 2015, is a thematic, research-oriented 
private equity firm that has been a "partner of choice" for China's most 
promising companies. LVC has left a mark in leading players such as Tik Tok, 
Didi, Bilibili, Junshi, InnoCare, Akeso, Pop Mart, SUPCON. In 2020, LVC was 
honorably awarded the "Top 10 Most Influential Private Equity Firms in China", 
"Top 20 Healthcare Investor in China", "Top 10 Innovative Drug Investor in 
China", and "Top 20 Consumer Investor in China".

About Lanting Capital

LanTing Capital (LTC) is a cross-border, pharmaceutical-focused strategic 
private equity firm. Founded by pharmaceutical veterans and asset management 
experts, LTC leverages our unparalleled industry knowledge and network plus 
deep financial market know-how across the USA, China and Europe to unlock 
unique cross-border growth opportunities for our portfolio companies and 
investors. LanTing is currently operating in Princeton (USA), Milan (Italy), 
Saanen (Switzerland), and Hangzhou (China). 

About TF Capital

TF Capital focuses on investment in the life sciences industry, primarily 
investing in early-stage companies with high potential.  Through strategic 
investments in various key areas and right partnerships, TF Capital hopes to 
capture opportunities in the rapidly expanding Chinese life sciences market. 
Our investment team has vast experience and resources in industry to assist our 
portfolio companies.

About Vertex Ventures China

Vertex Ventures is a global network of venture capital funds, who is a member 
of Tamasek Holdings. The operator-investors manage portfolios in China, the 
U.S., Israel, India and Southeast Asia. Vertex Ventures China, founded in 2008, 
has offices in Beijing, Shanghai and Shenzhen. It is currently managing both 
Dollar and RMB funds, with assets under management of over ¥10 billion. Vertex 
Ventures China invests in high-growth innovative start-ups across mainland 
China, covering the fields of deep tech, new digital economy and healthcare. 
Some of its notable investments include 91 Wireless, Chipscreen, mobike, 
Horizon Robotics, Harbour Biomed, Changba, Edge Medical, Inmagene, Infinovo, 
etc. 

www.regor.com

Source: Regor Therapeutics Group